Reactions of equimolar quantities of potassium 2-{[(2Z)-3-hydroxy-1-methyl-2-butenylidene]amino}acetate, with R n SnX4−n (R: benzyl– and n=2 or 3) in methanol yielded products of compositions LHSn(PhCH2)3 and LSn(PhCH2)2, respectively. The complexes were characterized by microanalysis, IR, NMR (1H, 13C, 119Sn) and 119mSn Mössbauer spectroscopy. A full characterization of the structure of the complex, tribenzyl{2-{[(2Z)-3-hydroxy-1-methyl-2-butenylidene]amino}acetato}tin(IV), was carried out by single crystal X-ray crystallography. The compound exists as centrosymmetric dimers in which two ligand molecules bridge the two tin centres. Each of the tin atoms in the dimeric unit is five coordinate in an approximately trigonal bipyramidal configuration, with carbon atoms in the equatorial positions and oxygen atoms arranged axially.

An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.

Three new triorganotin(IV) complexes, the trimethyl, tributyl and tpphenyl privatives of 5-(4chlorophenylazo)salicylic acid, have been synthesised and characterised by H, C, Sn NMR, IR and elemental analysis and the crystal structure of triphenyltin-5-(4-chlorophenylazo)salicylate is reported o .The crystals are monoclinic, snace group P2]/n with a = 9.566(1) Ä, b = 14.550(2)Ä, c = 22.528(3)Ä, ß= 94.04(1), V= 3127.8(7)A , Ζ = 4 and D ca l c = 1.42 Mg.mThere is an encapsulated molecule of hexane incorporated in the structure.This complex adopts a monomeric distorted tetrahedral configuration with the ligand coordinated via a carboxylate oxygen.

By means of cluster analytic techniques, four subtypes of psychosocial adjustment were identified in a sample of 122 breast cancer patients who completed the Psychosocial Adjustment to Illness Scale. Internal consistency and internal validity of the derived typology were suggested by the finding that two different hierarchical agglomerative clustering methods (average linkage between groups, Ward's) produced similar solutions. Three of the derived subtypes reported normal affect levels but different patterns of relative strengths and dysfunctions, while the fourth subtype appeared to be highly distressed and globally maladjusted. External validation was demonstrated by differentiating the subtypes on variables of negative affect, avoidance coping, and fighting spirit. The clinical and heuristic implications of these findings are discussed. The findings highlight the need for comprehensive assessment of psychosocial functioning of cancer patients. They demonstrate that even non-emotionally distressed patients can have very different profiles of adjustment and may benefit from correspondingly individually tailored psychosocial interventions.

The relationship of dispositional optimism, daily life stress, and domestic environment to two types of coping methods was examined in a group of 94 cancer patients. As expected, dispositional optimism and domestic environment made significant contributions to the prediction of avoidance coping. Dispositional optimism contributed significantly to the prediction of active-behavioral coping. Specifically, a significant positive relationship was obtained between active-behavioral coping and optimism. A significant positive relationship also was found between avoidance coping and both daily stress and domestic environment. Avoidance coping was negatively related to dispositional optimism. In multivariate analyses, gender and disease-related variables did not make significant contributions to the prediction of coping method. Suggestions for future research were made.

Nineteen patients receiving cancer chemotherapy were randomized in a double-blind fashion to receive either (a) dronabinol, 10 mg plus placebo q.i.d.; (b) prochlorperazine, 10 mg plus placebo q.i.d.; or (c) dronabinol plus prochlorperazine, each 10 mg q.i.d. There were six evaluable patients in each of the two single-agent groups and five in the combination group. The median duration and severity per episode of nausea was significantly greater in the group receiving prochlorperazine alone versus the other two groups. The median duration per episode of vomiting was also significantly greater in the prochlorperazine group than in the other two groups. The proportion of patients vomiting was the same in all groups; however, only one patient in the combination group versus three each in the single-agent groups experienced nausea (p = NS). The majority of side effects were associated with the CNS, including somnolence, dizziness, and confusion. Side effects were somewhat more common in both groups receiving dronabinol, though they were not statistically different from the side effects in the group receiving prochlorperazine as a single agent. Efficacy, as measured by duration of nausea and vomiting and by severity of nausea, was significantly greater in both groups receiving dronabinol.

This article reports a replication of an earlier study of how women cope with and adjust to breast cancer. Forty-nine women with breast cancer completed self-administered instruments that measured coping, fighting spirit, and psychosocial adjustment to illness. The results indicated that fighting spirit was related reliably to better psychosocial adjustment and that coping by avoidance was related reliably to poorer adjustment. Denial was not related reliably to any of the adjustment measures. Similarly, reliable relationships were not found between either disease status or duration of illness and adjustment to the illness.

Bis(2-carbomethoxyethyl)chloro(quinolin-8-olato)tin(IV), C17H20ClNO5Sn, crystallizes in the triclinic space group P1, with a 7.9001(7), b 10.2636(7), c 12.8287(9) Å; α 108.575(7), β 98.564(6), γ 96.469(7)°; V 960.69 Å3, Z = 2. The coordination geometry around the tin atom approximates to a skew-trapezoidal bipyramid, with the carbonyl oxygen of one of the 2-carbomethoxyethyl groups intramolecularly bonded to the tin (SnO 2.847(4) Å). This oxygen atom, the nitrogen and oxygen atoms of the chelating quinolin-8-olato ligand (SnN 2.370(4), SnO 2.040(4) Å; NSnO 74.4(1)°), and the chlorine atom (SnCl 2.454(2) Å), occupy the four corners of a trapezoid around the metal atom. The two apical tincarbon bonds (SnC 2.122(6), 2.143(7) Å), which are skewed towards the long edge (defined by the carbonyl oxygen and nitrogen atoms) of the trapezoidal plane, subtend an angle of 135.4(3)° at tin.

A standard methodology for the dissolution of a wide range of metallurgical analytical samples is described. The procedure involves peroxide fusion in a zirconium crucible, followed by dissolution of the cooled melt in an acid solution prior to inductively coupled plasma atomic emission spectrometric analysis. The method is rapid and cost-effective. The recovery of sulphur is almost total and separate combustion analysis is unnecessary.

Higher rates of recurrence-free survival at 5- and 10-year follow-up have been reported for breat cancer patients who initially responded to cancer with attitudes of “fighting spirit” or denial. We report here a factor analytic attempt, utilizing questionnaire data, to objectify these attitudes. A reliable factor structure replicated in breast and mixed cancer samples, yielding three factors: (1) Fighting Spirit or belief in the ability to fight back, conquer, and recover from cancer; (2) Information-Seeking behavior; and (3) Denial. Adequate 1-month test-retest correlations were obtained for Fighting Spirit and Information Seeking factor scores. A pattern of differential correlations with other measures (affect, coping, and optimism) distinguished Fighting Spirit and Information Seeking. The Denial factor appeared to be less stable and did not correlate significantly with other measures.

Eleven new complexes of the type Ph 3 SnX: o -HOC 6 H 4 CHNR (X = Cl, NCS; R = CH 3 , t -Bu, PhCH 2 , n -C 6 H 13 , c -C 6 H 11 , HOCH 2 CH 2 ) have been synthesized by the reactions of triphenyltin chloride or isothiocyanate with the N -alkylsalicylideneimines. The complexes are non-electrolytes in nitrobenzene. IR, PMR and Mössbauer spectroscopic studies indicate that the ligands are behaving as monodentates via the phenolic oxygen atoms, and that the complexes all have trigonal bipyramidal geometry with the phenyl groups occupying the equatorial positions.

Ferene iron reagent, 3-(2-pyridyl)-5,6-bis(2-(5-furyl sulfonic acid)-1,2,4-triazine, disodium salt, monohydrate, has been synthesized and characterized. Results of a study of its complex formation with iron(II) including λmax, εmax, and log K values are reported.

The synthesis and characterisation of a new colorimetric reagent for iron, 3-(2-pyridyl)-5,6-bis(2-furyl)-1,2,4-triazine are described. Peak assignments and chemical shifts of the high resolution 13C nmr spectrum are given. The reagent forms a tris iron(II) complex with epsilon max of 32000 Lcm-1 mol-1 at 577 nm. The results of precision, linearity and recovery studies for use of the reagent in direct serum iron determinations are reported. Thiourea effectively suppresses copper interference for the serum iron determinations. With the procedure used, the presence of hemolysed cells in the serum had no effect on serum iron levels recorded.

The SWOG carried out a Phase II evaluation of rubidazone in patients with advanced breast cancer. Good risk patients were given rubidazone 150 mg/m2 IV every three weeks. Poor risk patients were given a 25% dose reduction at the start of treatment. Rubidazone dose was increased or decreased depending on toxicity. One patient went into complete remission, four had partial remission and nine had stable disease. Forty-two patients showed increased disease on treatment. No cardiotoxicity was seen, but other common toxicities noted included mostly mild to moderate myelosuppression, nausea, vomiting and alopecia. This study failed to indicate significant antitumor activity of rubidazone in patients with advanced breast carcinoma.

Proton and 13C NMR data indicate that in their complexes with dimethyltin dichloride, the N-arylsalicylideneimines behave as monodentate ligands with oxygen, rather than imine nitrogen, as donor atom.

In March of 1972, the Southwest Oncology Group initiated a Phase II study, No. 7200, utilizing methyl-CCNU in the treatment of patients with solid tumors and lymphomas. Initially, they received 200 mg/m2 orally as a single dose every 6 weeks. The dose was subsequently reduced in poor-risk patients to 150 mg/m2. There were 69 responses noted in 675 evaluable patients (10%). The highest response rates were noted in patients with Hodgkin's disease (13/31, 35%), malignant gliomas of the brain (8/29, 28%), anaplastic carcinomas of the lung (5/20, 25%), and squamous cell carcinomas of the head and neck (5/29, 17%). Squamous cell tumors appeared to be more responsive than adenocarcinomas (15% vs. 5%, respectively). Hematologic toxicity was cumulative, and was influenced by dose and prior treatment. There appeared to be no cross-resistance in patients previously treated with alkylating agents. Methyl-CCNU is an active antineoplastic agent. Further studies are indicated in order to determine relative effectiveness.